KENDALL MAREADY: Open Payments
NPI 1922613215 · GREENVILLE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$230 in 12 payments from 9 companies in 2025. Trend: 2023 $130 · 2024 $178 · 2025 $230
Food & beverage: $230
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $33 |
| ABBVIE INC. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Amgen Inc. | 1 | $16 |
| Novo Nordisk Inc | 1 | $14 |
Products named: REXULTI, LEQVIO, VRAYLAR, HETLIOZ, AIRSUPRA, XIFAXAN, GEMTESA, OTEZLA.
Industry payments across NC — which companies pay providers there.
